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Faculty Mentor: Professor David Osterberg 
Abstract 
This study focuses on determining an effective public health policy strategy to address 
agricultural antibiotic resistance. The research examines domestic and international examples of 
governmental regulation, including the Food and Drug Administration’s regulatory release, 
Guidance for Industry #213 (FDA GFI #213), which concerns the use of antibiotics in industrial 
livestock farming in the United States, and the contrasting Danish policy and surveillance 
techniques. To determine the effectiveness of voluntary measures, this research assesses 
motivations leading to the creation of FDA GFI #213 by referencing specific legal disclaimers, 
document audience, and enforcement methods. Taking these results, the study cross-examines 
the goals of FDA GFI #213 with annual FDA reports on rates of agricultural antibiotic use from 
2009 through 2016. This study concludes that FDA GFI #213 has not contributed to a significant 
decline in agricultural antibiotic use. Therefore, voluntary regulation alone is thus far shown to 
be ineffective in confronting antibiotic resistant pathogens. A combination of mandatory and 
voluntary policies has been proven successful through the Danish method of precise surveillance 
and mandatory regulation. This study intends to contribute to the ongoing debate on policy 
approaches in combatting the proliferation of antibiotic resistance a culmination of industrial 
agriculture farming practices, legislation, and global human health. 
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Significance of Research 
The significance of this study rests in its focus on the ever-growing threat of antibiotic 
resistance to global human and animal health. In recognition of the critical state of antibiotic 
overuse in agriculture, in 2016, the Expert Commission on Addressing the Contribution of 
Livestock to the Antibiotic Resistance Crisis developed eleven recommendations necessary for 
constructive progress (see graphic 1) (Expert Commission). George Washington University 
Milken Institute School of Public Health (GWSPH) and the Natural Resources Defense 
Council helped to organize and endorse the Commission, which is made up of twelve 
antibiotic-resistance specialists, including infectious diseases physicians, veterinarians, 
epidemiologists, microbiologists, pediatricians (Expert Commission). The Commission later 
released a comprehensive report estimating that by 2050, over ten million deaths annually will 
occur due to antibiotic resistance (Expert Commission). According to Dr. Lance Price, the co-
chair of the Commission, “Antibiotic resistance is one of the greatest health threats of our time” 
(Expert Commission). Assessing the public health impact of voluntary regulations is vital; the 
Centers for Disease Control and Prevention (CDC) estimates that antibiotic resistance causes 
over two million infections and 23,000 deaths annually in the U.S. alone. According to the 
Health Assembly of the World Health Organization (WHO), antibiotic resistance “poses a 
profound threat to human health.” This honors thesis serves as case study on the effectiveness of 
voluntary measures versus mandatory regulation in confronting a single aspect concerning the 
problem of antibiotic resistance in agriculture. The compilation of research finds that all 
antibiotic use must be part of a multi-faceted proactive health policy to insure proper response 
and mitigation of health risks. Researching economic, legislative, and health impacts of FDA 
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GFI #213 contribute to the discourse on fighting antibiotic resistance in the food system 
worldwide. 
Graphic 1 
 
Source: Expert Commission on Addressing the Contribution of Livestock to the Antibiotic Resistance Crisis, Summary of 
Roadmap Recommendations, 2017; pg. 2. 
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Introduction: Background and Global Relevance of Topic 
The discovery of antibiotics in the early 1930s revolutionized the science of medicine—
disease mortality rates plummeted by 75% in the first 15 years of use (Orrico). The effectiveness 
of antibiotics during this time was considered miraculous, with the ability to treat previously 
grim diagnoses like meningitis with relative ease. It was not until the 1950s that researchers 
discovered a breakthrough in agricultural antibiotic use: low doses of antibiotics given to 
livestock regularly could prevent disease and promote growth, thus food animals reached 
slaughter weight faster (Orrico). Thus, in 1951, the FDA sanctioned antibiotics for use in growth 
production without veterinary prescription (Laxminarayan). At first, studies conducted before the 
1980s indicated that antibiotic growth promoters quickened the livestock growth rate by as much 
as 5-15% (Laxminarayan). However, by the 2000s, this rate was less than 1%, and labelled as not 
significant (Laxminarayan). Nonetheless, non-therapeutic use is widely used in the modern 
concentrated animal feeding operations (CAFOs) that dominate the global livestock industry. As 
the name implies, CAFOs raise a large population of food-producing animals in a small area of 
space to maximize profits. Sadly, 99% of food-producing animals never step foot outside 
production facilities (Boris). The subsequent close quarters facilitate outbreaks of disease among 
the animals. To combat this, CAFOs mix low doses of antibiotics into the feed and water of the 
livestock in order to prevent illness and expedite weight gain. This non-therapeutic use of 
antibiotics has contributed to the rise in antibiotic resistant pathogens, some of which are 
immune to even the strongest antibiotics known to science (Orrico). Global examples, such as 
Denmark, illustrate how any negative impact of banning non-therapeutic antibiotic use can be 
counteracted through improvements in hygiene, feed, and production practices (Laxminarayan). 
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Graphic 2 
 
Source: Centers for Disease Control and Prevention, Antibiotic Resistance from the Farm to the Table, Dec. 2017. 
As pictured in graphic 2, these “super-bacteria” are passed to humans via the food or water 
supply, environmental waste contamination, and direct transmission from contact with infected 
animals (CDC). Public health researchers in China, Denmark, and the United States compiled 
data that indicated a rise in antibiotic-resistant environmental contamination from livestock 
waste, which warned agricultural antimicrobial resistance (AMR) as a crisis without national 
borders. As this research will demonstrate, the United States employs a select few Danish tactics 
to address agricultural AMR, yet displays many of the weaknesses of the Chinese approach.  
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Industrial farming practices have been adopted for use worldwide, including in Asia, 
parts of Europe, and South America. As the average income has steadily risen, so has the 
demand for meat, poultry, and animal products. As an example, China yields and consumes more 
than 500 million head of swine, more than half of the world total, and is the world’s top meat 
producer (Collignon). Currently, there are no official bans on using antibiotics for production 
purposes, and antibiotics can be used with food-producing animals without any form of 
veterinary oversight (Maron). Ying et. al estimates that over half of antibiotics sold in China are 
supplied to food-producing animals (Ying et al). High levels of antibiotic resistant bacteria have 
been detected in animal fecal waste that contaminates nearby waterways (Collignon). The 
Chinese Ministry of Agriculture addressed agricultural antibiotic overuse as far back as 1987, but 
due to poor enforcement, little progress has been made; there is still a pervasive lack of 
surveillance and regulation (Ying et al). This suggests an economic bias over public health 
concerns. 
In Denmark, however, efforts to reduce agricultural antibiotic use have facilitated success 
as well as domestic and international support. By 1999, medical researchers, farmers, public 
health officials, and Danish legislators, eliminated non-therapeutic antibiotic use in swine 
production. From 1994 through 2016, antibiotic use in all animals fell by 49%, while production 
of food animals actually increased by 15% (“DANMAP 2016”). This led to a decline in 
antibiotic-resistant bacteria in swine and human fecal matter—demonstrating the effectiveness of 
reducing agricultural antibiotic use in regards to both human and animal health (Levy). The 
integrated industry and policy approach in Denmark balances economic and public health 
interests. 
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Denmark Examination 
 European countries such as Denmark garnered striking success in banning agricultural 
antibiotic use for production purposes. As early as the 1960s, the EU prohibited medically 
important antibiotic use in agriculture for growth-promoting purposes, but the scope of the 
regulation was limited to a small number of drug classes (Levy). According to Hammerum et al, 
“Denmark was the first country to establish a systematic and continuous monitoring program of 
antimicrobial drug consumption and antimicrobial agent resistance in animals, food, and 
humans” (Hammerum et al). This comprehensive surveillance system is known as the Danish 
Integrated Antimicrobial Resistance Monitoring and Research Program (DANMAP), and 
continues to collect vital data used in epidemiological and public health research today. Before 
tackling the complexity of banning nontherapeutic antibiotic use in food-producing animals, 
public health researchers established a strong foundation of evidence based in science—rates of 
antibiotic resistance found in farmers and livestock treated with antibiotics (Levy). In 1994 and 
1995, researchers in Denmark discovered a link between non-therapeutic use of avoparcin in 
food-producing animals and high levels of vancomycin-resistant Enterococcus faecium (VREF) 
on farming operations. Since avoparcin is one of only a select number of drugs able to treat 
resistant VREF, in spring of 1995, the Danish Minister of Agriculture and Fisheries completely 
outlawed agricultural use of avoparcin (Hammerum et al). This triumph in public health was 
possible because of the effective non-political scientific evidence collected, thus demonstrating 
how public health and governmental spheres can cooperate. Later after this pronouncement, EU 
administrators followed the Danish lead and adopted the avoparcin ban (Hammerum et al). 
However, Denmark incorporated a holistic approach to reducing antibiotic overuse by addressing 
industry pressures—namely that veterinarians received incentives for prescribing antibiotics. 
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According to Levy, at one point, veterinarians received a third of their salary from prescription 
quota incentives (Levy). To remedy this, the Danish government enacted regulations restricting 
profits that veterinarians could receive from drug sales. Throughout the late 1990s, Denmark 
continued to monitor environmental antibiotic resistance and by 1999, eradicated all non-
therapeutic antibiotic use in swine operations (Levy).  
The US Approach: Description of FDA GFI #213 
 Regulating agricultural antibiotic use in the United States has a complex history. In 1978, 
the FDA harbored significant concerns about antibiotic resistance arising from production uses 
(Eskridge). The FDA proposed three strategies: banning all Penicillin use, only using 
tetracyclines for treating disease, and controlling dispensing through registered feed mills by 
order of a veterinarian (Eskridge). This was met with uproar in Congress, with fifteen senators 
citing increased production costs for farmers and a lack of concrete scientific evidence proving 
that production uses of antibiotics cause antibiotic resistance in humans. Since then, the FDA has 
been reluctant to take a hard stance with mandatory regulation of antibiotic use, which has 
resulted in the United States using 13% of the world’s total antibiotics in agriculture, second only 
to China (Expert Commission). The situation has not improved since then, with antibiotic 
resistance continuing to proliferate. 
 Today, despite the presence of a goldmine of international research, there is still the 
pervasive and willful disbelief in the connection between agricultural antibiotic resistance and 
human infection throughout the agricultural industry in the United States. This is due to a 
fundamental difference in public health principle comprehension between the U.S. and the E.U. 
The E.U. operates under a more literal understanding of the “precautionary principle”, being 
proactive “when evidence points toward the potential of an activity to cause significant 
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widespread or irreparable harm to public health or the environment, options for avoiding that 
harm should be examined and pursued even if the harm is not yet fully understood or proven” 
(Marshall and Levy). Part of the reason for the U.S. reluctance is due to the fact that there has not 
been a definitive study like the Danish ban of avoparcin use in livestock resulting in heightened 
VREF bacteria levels in humans. This is a glaring absence in epidemiological and environmental 
health research in the United States that demonstrates genetic zoonotic potential. Thus, scientific 
studies back-tracing resistance genes found in humans to their agricultural source is a pressing 
need (Schmidt). These studies have only recently begun (Schmidt). However, there are cases of 
infection by consumption and exposure to sick animals. For example, in 1985, there was an 
outbreak of drug-resistant Salmonella in California that sickened 1000 people, and was later 
attributed to meat from dairy cows (Khachatourians). Multiple studies indicate transmission 
through animal products to humans, finding that both the product and the human fecal matter 
contain the same resistant bacteria (Marshall and Levy). Additionally, researchers discovered 
that the DNA of resistance genes in both humans and animals is completely identical (Schmidt). 
Furthermore, in 2000, the National Antimicrobial Resistance Monitoring System (NARMS) 
concluded that based on human Salmonella samples, 12% was impervious to five of the major 
drugs also used in agriculture (Schmidt). This gives credence to the likelihood of resistance 
transmission between humans and food-producing animals. Though these studies provide 
support as evidence of the possibility of agricultural use in the U.S. directly causing resistance 
proliferation in humans, a large-population study truly demonstrating this connection is still in 
progress.  
 Recently Smith and Heitman conducted research exploring the connection between 
specific strains of human and livestock associated MRSA. Smith and Heitman acknowledged the 
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difference in data results between Europe and the United States. Specifically, the CC398 strain 
found in humans in Europe was traced back entirely to livestock sources (Smith and Heitman). 
However, the in United States, CC398 was found in both agricultural and non-agricultural 
locations. When livestock have human MRSA strains, and humans have livestock-associated 
MRSA strains, researchers have difficulty determining the true genetic source. The study 
concluded that people that lived near CAFOs had a significantly higher risk of MRSA infection, 
though the MRSA bacteria was not livestock-associated (Smith and Heitman). According to 
Smith and Heitman, this would suggest that either new strains of MRSA are evolving on farms, 
or that antibiotic-resistant genes are being transferred to humans and proliferating. Ultimately, 
Smith advocated for national, large-scale sampling on agricultural operations to give detail to 
this complex phenomenon.  
According to the CDC, 70% of antimicrobials in the U.S. are used in livestock production 
(Expert Commission). Public concern and congressional pressure fueled an FDA regulatory 
response in the form of FDA GFI #209, and most recently, FDA GFI #213 in 2013. FDA GFI 
#209 outlines principles of judicious use of antimicrobials in agriculture, while GFI #213 
provides the voluntary measures for producers to take in order to achieve two major goals: 
“Limit medically important antimicrobial drugs to uses in animals that are considered necessary 
for assuring animal health, and limit medically important antimicrobial drugs to uses in animals 
that include veterinary oversight or consultation” (FDA GFI #209, FDA GFI #213). 
As a part of the strategy to regulate agricultural antibiotic distribution, the FDA 
categorizes dispensation methods into three categories: Veterinarian Feed Directive (VFD), 
prescription (RX), or over-the counter (OTC). OTC products are available to purchase and use 
without veterinary oversight or written permission and can be found in most feed stores. VFD 
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and prescriptions both require veterinary supervision and a written order required to buy the 
drug. VFD is mandatory for any feed-based antimicrobial product, while a prescription is 
required for all other routes of administration. The FDA intended to enact veterinarian oversight 
to antimicrobials administered to food-producing animals by route of feed or water (FDA GFI 
#213). As many of these antimicrobials have OTC dispensing status, the FDA created a series of 
voluntary guidances to shift labelling to prescription or VFD status. However, the non-
mandatory nature of FDA GFI #213 has come under fire due to lack of drug use surveillance, 
regulatory ambiguity, indefinite goals, lenient enforcement, and poor results. 
Limitations of FDA GFI #213 
Guidance for Industry #213 is limited in its abilities to reduce antibiotic resistance 
because of its voluntary nature and focus on economic impacts rather than public health 
implications. The FDA has been aware of the possible health threat of antibiotic resistance 
arising from nontherapeutic agricultural antibiotic use since before 1977. At that time, the FDA 
rejected calls to place restrictions on non-therapeutic use, citing concerns about profit 
consequences from increased production costs for producers, suggesting a bias towards industry 
(Orrico). Additionally, the details of executing GFI #213 are negotiated privately between the 
FDA and pharmaceutical companies. Heinzerling believes that this will keep the public unaware 
about the progress of the voluntary measures for years to come (Heinzerling). GFI #213 states 
that the “FDA believes it is critically important that changes such as these be implemented to 
minimize impacts on veterinarians, the animal feed industry, and animal producers” (FDA GFI 
#213). While this serves to make the transition to prescription labelling and veterinary oversight 
more palatable for these parties, the time-sensitive nature of limiting the progress of antibiotic 
resistance is not emphasized enough. Therefore, preemptive and efficient action is necessary to 
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hinder the development of even stronger antibiotic resistant pathogens. Further instances in the 
directive’s language indicate possible enforcement weaknesses. 
In contrast, there are studies that support the use of antibiotics in agriculture because of 
the benefit to animal welfare and securing the human food supply. Animal Health Institute 
spokesperson Ron Phillips defended the use of non-therapeutic antibiotic use, “And to date, no 
one has found an alternative that can match antibiotics for disease control on the scale at which 
we produce food today—at least not one which allows consumers to buy meat at such low 
prices” (Schmidt). This statement aligns with Hao’s stance that antibiotics help manage the 
growing demand for food. For example, antibiotics given to swine results in increased 
conception and milk production, lower piglet mortality rate, and faster weight gain, thus 
increasing the population (Hao). Furthermore, antibiotic use also prevents the spread of zoonotic 
pathogens to humans through the food supply (Hao). Hao stated that antibiotics, “could 
significantly decrease the bacterial contamination in animal products” (Hao). Antibiotic feed 
additives result in decreased bacterial contamination within animal carcasses, thus limiting the 
infection risk to humans (Hao). Hao concluded that even though the studies demonstrating the 
benefits of antibiotic use were limited in scale and explanation, “It is undeniable that rational use 
of antimicrobials plays a vital role in the production of food animals and protecting public 
health” (Hao). Therefore, agricultural antibiotic use protecting food security is a public health 
counter-claim. 
However, there are significant concerns with Hao’s argument. For example, even though 
animal carcasses may have decreased bacteria, this does not pay homage to the fact that the 
products from these animals includes low-doses of antibiotics (Boris). It is possible that these 
food-producing animals carry resistant bacteria without showing any clinical symptoms, and pass 
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the meat inspection process (Boris). Hao also ignored the problem of environmental 
contamination as a public health concern. According to the USDA, livestock create 500 million 
tons of manure per year (Boris). Coupled with the fact that up to 75% of antibiotics fed to 
livestock are present in their manure, this proves to be a serious issue, not to be pushed aside in 
favor of cheap meat (Boris). In fact, a consumer survey conducted by the Review on 
Antimicrobial Resistance concluded that 86% of consumers would like antibiotic-free animal 
products, and 60% of those surveyed were willing to pay more for it (“Review”). Healthcare 
costs to the consumer from an antibiotic resistant infection are far higher than the comparably 
negligible price increase in animal products that would be a result of banning non-therapeutic 
drug use. For example, it is estimated that human disease resulting from non-therapeutic 
agricultural drug use piles on more than $50 billion to the cost of healthcare in the United States 
(Boris). In addition, the cost advantage in production possible through non-therapeutic antibiotic 
use may be trifling compared to the substantial export losses, according to Landers et al.  
Landers et al addressed the possible large-scale economic consequences of not increasing 
agricultural antibiotic control. In the study, researchers collected agricultural antibiotic regulation 
data from seventeen different countries that are trade partners with the United States. The 
conclusion was that the majority among these trade partners have stricter limits on antibiotic use, 
including mandatory veterinary oversight. According to Landers et al, because the FDA 
continues to support use of antibiotics for disease prevention, this could prove to be a 
disadvantage for U.S. exports of food animal products. For example, Landers et al found that 
since 1997 when the European Union banned U.S. poultry imports because of antimicrobial rinse 
residue, U.S. imports went from 52 million dollars to 13 million dollars as of 2011 (Landers et 
al). Most trade partners that import American animal products have stricter policies, such as 
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Sweden, Denmark, and the Netherlands (Maron). Therefore, antibiotic policy trade barriers 
abroad account for a loss of export revenue that may rival an increase in production costs due to 
more stringent antibiotic regulation The environmental pollution and skyrocketing health costs 
because of agricultural AMR perhaps eclipses the food availability counter-argument.  
GFI #213 was written as a voluntary guideline in order to ensure efficiency in the 
overhaul process (Rosso Grossman). According to the FDA, the document, “do[es] not establish 
legally enforceable responsibilities” (FDA GFI #213). Instead, guidances describe the FDA’s 
current thinking on a topic and should be viewed only as recommendations, unless specific 
regulatory or statutory requirements are cited. The use of the word ‘should’ in the FDA’s 
guidances means that something is suggested or recommended, but not required” (FDA GFI 
#213). This disclaimer denies legislative power, and instead operates through the soft power of 
suggestion. However, guidances lack enforcement methods or legal consequences for infractions. 
FDA GFI #213 is linked to multiple regulatory documents, such as FDA GFI #209 and the 
Veterinary Feed Directive (VFD), in a concentrated effort to convince producers and 
pharmaceutical companies to regulate antibiotic usage through changing label wording. Before 
1993, antibiotics were available over the counter for animal feeding operations as feed and water 
additives. If pharmaceuticals edit labels to state the necessity of veterinary supervision, only 
approved usage would be possible, since it is currently against the law to use an antibiotic for 
extra-label purposes. Although this helps in tracking antibiotic use and controlling the conditions 
in which antibiotics are prescribed, there are a number of issues, such as oversight consistency 
and geographical limitations. A key facet of the document is veterinary management in 
prescribing antibiotics. The veterinarian carries responsibility for deciding if/when/how an 
antibiotic is able to be judiciously used. Since this can be subjective, training, education, and 
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further veterinarian presence would be necessary to prescribe based upon a common definition of 
judicious use. Unlike in Denmark, there is no limit to veterinarian profits, and no subsequent data 
on prescription rates per each veterinarian (Expert Commission). This is an issue due to the lack 
of accountability for veterinarians to use antibiotics in a prudent manner. Rural and small-scale 
farming operations may not have access to regular veterinary care, limiting the geographic scope 
of FDA GFI #213’s area of effectiveness. According to Heinzerling, the release of the VFD 
undermines the veterinary oversight conditions present in FDA GFI #213. VFD essentially 
reduces the frequency of veterinary documentation, working against previous requirements 
(Heinzerling; Rosso Grossman). This represents a fundamental conflict within the FDA GFI 
#213 in regards to combatting agricultural antibiotic resistance. 
New antibiotics are the primary focus of FDA GFI #213. This is relevant because it 
suggests the FDA is trying to address agricultural antibiotic resistance proactively, which is an 
effective tactic, but may draw attention away from older antibiotics still in use. For example, as 
of 2003, the FDA requires safety reviews for every new veterinary antibiotic as a pre-approval 
process. Despite this, the majority of antibiotics given to food animals as growth enhancers, 
disease prevention, and other non-therapeutic applications are exempt, because the FDA 
approved them before 2003 (IDSA). According to Heinzerling, voluntary measures, “guarantee 
little more than continued delay in tackling a public health risk” (Heinzerling). Heinzerling 
further explains that there are key weaknesses in FDA GFI #213. The FDA still endorses sub-
therapeutic use of antibiotics to prevent disease; this means that antibiotics could still be used on 
a mass scale, even without active infection present. Furthermore, the success of FDA GFI #213 
relies upon the cooperation of pharmaceutical companies, which are driven by profit. Twenty-
five out of twenty-six pharmaceutical companies contacted by the FDA have accepted the 
Drake 16 
 
voluntary initiative to re-label drugs from over the counter to prescription or veterinary 
oversight. While this is positive on the surface, these companies have not agreed to do this for 
every drug, and there are currently legal disagreements over which drugs are considered 
medically important. Heinzerling suggests that even though production uses of antibiotics may 
be phased out, companies will merely use the aforementioned loophole and label the drugs under 
disease prevention. The suggestions of FDA GFI #213 have an implementation phase of three 
years, however, the FDA has not outlined a clear back-up plan in case of failure (Heinzerling).  
According to FDA GFI #213, “If, after the period of evaluation of the three-year phase in, 
[the FDA] determine[s] that adequate progress has not been made, [the FDA] will consider 
whether further action under the existing provisions of the FD&C Act may be appropriate” 
(“FDA GFI #213”). This deliberately vague statement appears to be a veiled threat for 
mandatory regulation in the wake of non-compliance. However, the lack of specificity regarding 
clauses of the FD&C Act and their consequences undermines the authority of the statement. 
Furthermore, even the three-year adoption period is not concrete. Again, the FDA contradicts 
their authority by hedging, “Although FDA is committed to completing this rulemaking process 
within the 3-year timeframe for implementing the changes discussed in this guidance, FDA is 
prepared to extend the timeframe, as necessary, to ensure that it coincides with the 
implementation of the revised VFD requirements” (“FDA GFI #213”). This essentially writes a 
blank check to pharmaceutical companies for adopting the necessary changes, and renders the 
threat of mandatory legal action a mere bluff. Thus, these gaps in regulation allow for the 
continued antibiotic misuse that contribute to antibiotic resistance. 
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How Effective is FDA GFI #213? 
 Since the inception of FDA GFI #213 back in 2013, the ultimate goal was to gradually 
implement measures to re-label medically important antibiotics from OTC to VFD or 
prescription, with all claims for production uses removed. To monitor the progress of GFI #213, 
the FDA releases an annual report that contains data estimates for antimicrobial drugs approved 
for use in food-producing animals. This document includes the drug class, medical importance 
status, and dispensation method. Recently, in December 2017, the FDA released the “FDA 2016 
Summary Report on Antimicrobials Sold or Distributed for Use in Food-Producing Animals” to 
the public. 
 There was recent positive progress regarding the implementation of FDA GFI #213 
between 2015 and 2016. According to the FDA’s 2016 Summary Report, the overall sales and 
distribution of approved antimicrobials for food-producing livestock in the United States fell by 
10%. In comparison, from 2014 to 2015, the overall total increased by 1%. This decrease is 
indeed a welcome change. In 2015, 62% of all antimicrobials sold domestically were categorized 
as medically important to human health. This percentage fell by a mere 2% in 2016 to 60% 
(“2016 Summary Report”).  Nevertheless, the majority of antimicrobials used on food-producing 
animals continue to be medically important. Reducing the consumption of these vital groups of 
antimicrobials is essential to preserving the efficacy of antibiotic treatments in humans. 
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United States 2016 Production Totals and Medically-Important Antibiotic Sales 
Food-Producing Animal Production (millions) Antibiotics Distributed (kg) 
Cattle 92.0 3,610,943 
Swine 67.6 3,133,262 
 
Source: United States Food and Drug Administration, 2016 Summary Report On Antimicrobials Sold or Distributed for Use in 
Food-Producing Animals, Dec. 2017. 
Even though the 2016 report indicated a 10% decrease in antibiotic sales from 2015 to 
2016, one of the key issues hindering the fight to reduce antibiotic use is the lack of 
thoroughness in FDA data collection. The table above is an example of how the FDA now 
records livestock population with aggregate antibiotic totals. The 2016 report displays this latest 
addition to antibiotic surveillance—estimated amounts of antibiotics administered categorized by 
species. However, this update has been far too long removed. Alarmingly, the FDA only began 
collecting antibiotic use data by species in 2016.  
U.S.  2009-2016 Swine Production Totals and Medically-Important Antibiotic Sales 
Year 2009 2010 2011 2012 2013 2014 2015 2016 
Production 
(millions) 
65.4 64.0 64.0 64.9 65.9 62.9 65.9 67.6 
Antibiotics 
Distributed 
(kg) 
--  -- -- -- -- -- -- 3,133,262 
 
Source: USDA, Quarterly Hogs and Pigs, 2009-2016; FDA, 2016 Summary Report On Antimicrobials Sold or Distributed for 
Use in Food-Producing Animals, Dec. 2017. 
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This means that for the duration of the adaptation period of FDA GFI #213, the FDA did not 
collect specific records of antibiotic use broken down by species. The table above contains the 
total production of swine in the United States, along with the estimated amount of antibiotics 
used. The USDA records the population totals of both cattle and swine, while the FDA provides 
the antibiotic estimates. The blank spaces in the table section for antibiotic distribution serves as 
a visual representation of the vitality of complete data collection. However, even without 
species-specific data, the argument for non-therapeutic use weakens. According to the table 
above, the swine population from 2009 through 2016 has been relatively stable. This indicates 
that though until 2015 antimicrobial use continued to rise, production has not followed suit. 
Determining areas of overuse and taking steps to address the situation is possible only with 
detailed data. This is a tactic long used by DANMAP in Denmark and provides a baseline for the 
amounts of drugs target groups of livestock are consuming.  
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Table 1 
 
Source: United States Food and Drug Administration, 2016 Summary Report On Antimicrobials Sold or Distributed for Use in 
Food-Producing Animals, Dec. 2017; table 6. 
In Table 1, taken from the FDA Annual Report for 2016, the totals of medically 
important antimicrobial drugs are given based on dispensing status. Prescription and VFD 
dispensing make up less than 5% of annual antimicrobial consumption. This is problematic, as 
OTC drug use continues to be unregulated. Observing trends from 2015 to 2016 in Table 2, the 
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dispensing category of antimicrobials continued to dominate as OTC, from 97% to 96%, despite 
the relabeling efforts of FDA GFI #213 (“2015 Summary Report”).  
Table 2 
 
Source: United States Food and Drug Administration, 2016 Summary Report On Antimicrobials Sold or Distributed for Use in 
Food-Producing Animals, Dec. 2017; table 13b. 
The examination of antibiotic distribution data over a broader period of time 
overshadows the progress of FDA GFI #213 touted in the 2016 report; the success outlook is 
bleak. As said before, the annual reports released by the FDA began in 2009. The data trends 
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between 2009 through 2016 reflect the general status and effectiveness of FDA GFI #213 in the 
present. Over this span of years, the domestic sale and distribution of antimicrobials actually rose 
11% by the end of 2016 (“2016 Summary Report”).  
While the 2009 through 2016 total reflects both before and after the introduction of FDA 
GFI #213, it is vital to include both time periods in order to understand the true impact of FDA 
GFI #213. To further strengthen this point, even looking at the data from 2013 through 2016, 
there was a marked increased until 2016, when the total antimicrobial sales began to slightly 
decrease.  
Table 3 
 
Source: United States Food and Drug Administration, 2016 Summary Report On Antimicrobials Sold or Distributed for Use in 
Food-Producing Animals, Dec. 2017; table 12b. 
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Most notably, the summative sales and distribution of antimicrobials for production and 
therapeutic usage has only declined from 72% in 2009 to 69% in 2016. Table 3 displays the full 
range of percentages from 2009 through 2016 (“2016 Summary Report”). One of the foremost 
objectives of FDA GFI #213 is eliminating antibiotics used for production purposes. However, 
there is a gap in the data collection and formatting for the FDA’s annual report. Due to privacy 
protection procedures for businesses, the FDA cannot provide the information regarding 
medically important drugs used for production reasons—in lieu of this, sole production is 
combined with therapeutic use. However, the FDA estimates that 10% to 15% of antibiotics are 
still used for growth enhancement purposes only (Expert Commission). Separating production 
use from therapeutic use is currently not possible with current FDA protocols. Therefore, it is 
problematic when determining the progress of reducing nontherapeutic antibiotic use in 
agriculture through the amounts and allocation of antimicrobials in these reports. This blatant 
subterfuge is an example of FDA industry partiality.  
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Table 4 
 
Source: United States Food and Drug Administration, 2016 Summary Report On Antimicrobials Sold or Distributed for Use in 
Food-Producing Animals, Dec. 2017; table 5. 
According to Table 4, even in 2016, only 31% of antibiotics important to human health are used 
solely for therapeutic use in food-producing animals. Furthermore, only 4% of the total amount 
of medically-important antimicrobial drugs are dispensed as prescription or through VFD. After 
all of the emphasis on relabeling in order to transition OTC antimicrobials to VFD or 
prescription, the data reflects only a faint rise from 2% in 2009 to 4% in 2016. Based upon these 
Drake 25 
 
comparisons, FDA GFI #213 has not led to a significant decrease of antimicrobials used in food-
producing animals. The reports in subsequent years will continue to demonstrate the efficacy or 
ineptitude of FDA GFI #213; in particular, January 2017 marked the deadline for the execution 
of these modifications. The FDA’s 2017 annual report will be released in December 2018, and 
will contain data representing the full extent of FDA GFI #213’s regulatory scope. 
Though these documents embody progress in industry scrutiny and data collection, there 
are several vital constraints and inadequacies within the FDA’s annual reports. Near the 
beginning of the document, there is a significant disclaimer on the reliability of the figures and 
information. According the FDA GFI #213, “…the sales and distribution data submitted by 
animal drug sponsors and summarized in this report are not indicative of how these antimicrobial 
drugs were actually used in animals.” This connotes veterinarians condoning the extra-label use 
of antibiotics for a different therapeutic reason or for use with another species. Because each 
drug is typically able to be used for multiple reasons, it is difficult to pinpoint the exact purpose 
and treatment details. Another restraint to the faculty of the annual reports is the omission of any 
data that could be isolated to a drug or livestock producer. This is in order to protect confidential 
business information. However, without specific and detailed surveillance of agricultural 
antibiotic use in regards to geographic regions and individual operations, accountability of 
judicious use may be inhibited. With this, the FDA demonstrates an industry bias over public 
health. These are details to consider when determining the effectiveness of FDA GFI #213 when 
evaluating the FDA’s annual agricultural antibiotic sales and distribution summary reports with 
Denmark’s annual DANMAP releases. 
 
 
Drake 26 
 
Denmark’s Remarkable Surveillance System 
In comparison to Denmark’s wide-sweeping and dynamic approach to curbing 
agricultural antibiotic use, FDA GFI #213 does not have neither the immediate nor long-term 
results. The table below contains DANMAP data dating back to the early 1990s. When 
researchers initially collected livestock population data, pharmaceutical companies submitted 
antibiotic sales and distribution as a lump sum for all food-producing animals (“DANMAP 
2001”). However, after a major conference on AMR in Copenhagen in 1997, Danish legislators 
and public health officials initiated the VetStat programme in order to close the accuracy gap in 
surveillance between human and animal antimicrobial consumption. This innovative system 
required veterinarians and feed mills by law to submit detailed information on antimicrobial use. 
As a result, in 2001, DANMAP annual reports now included detailed tables with antimicrobial 
consumption by species and age. Interestingly enough, there were notable discrepancies between 
VetStat totals and totals provided by pharmaceutical companies. DANMAP concluded that this 
improved accuracy was vital in monitoring resistance rates and compliance with regulations. 
Each year, VetStat collects the production of each type of livestock, along with antibiotic use 
broken down by stage of life. This compilation of detailed information debunks common 
misconceptions plaguing antibiotic reduction efforts.  
To further denote the weaknesses of the FDA’s approach to curbing agricultural 
antibiotic use, examples from both Denmark and U.S. are provided below. The visual and 
informational contrast of the FDA’s annual surveillance reports and Denmark’s DANMAP 
releases is undeniable. The first table below is the 2016 general antimicrobial sales in Demark. 
The second one is the FDA’s equivalent table for 2016. Notice the differences in data 
collection—age and drug type is given in DANMAP, while the FDA table only gives sums by 
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species. This omission creates difficulties when determining where, how, and when dosing takes 
place during livestock production processes.  
2016 Antimicrobial Agents Sold in Denmark 
 
Source: Danish Integrated Antimicrobial Resistance Monitoring and Research Programme, DANMAP 2016, Oct. 2017; table 4.1. 
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2016 Antimicrobial Agents Sold in United States 
 
Source: United States Food and Drug Administration, 2016 Summary Report On Antimicrobials Sold or Distributed for Use in 
Food-Producing Animals, Dec. 2017; table 2b. 
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Is This Enough to Expect from the U.S. Program? 
 One of the central arguments contradicting antibiotic reduction was the rise of production 
cost due to higher rates of livestock mortality. However, Danish farmers transformed animal 
husbandry procedures, and the results have been astounding. The agricultural system in Denmark 
has a different structure when compared to the United States. Though there are many large 
livestock operations, most are privately owned. Farmer cooperatives manage all aspects of 
production, such as slaughter and dairy plants. In turn, this fosters a sense of accountability and 
pride within the farming community (Levy). For example, instead of separating sows from 
piglets immediately and supplementing the piglets’ with low-dose antibiotics, sows and piglets 
remain together for a longer period of time, so that the piglets can build a strong immune system 
from their mothers’ milk. This reduced the later need for antibiotics.  
Samples collected from swine since the avoparcin ban in 1995 indicate decreased rates of 
VREF (Levy). According to data collected by Van den Bogaard AE, et al in the Netherlands, 
VREF amounts decreased in both swine and humans (Van den Bogaard AE, et al). In regards to 
increased cost and mortality, after an initial mortality increase in swine in the years directly 
proceeding the 1995 and 1999 edicts, populations flourished. In 1992, the total of weaning pigs 
was only 18.4 million. By 2008, production had increased to 27.1 million (Levy). The production 
cost of each pig from birth to slaughter has increased by a single euro, equating to about 1% 
(Levy). The table below lists swine production alongside antibiotic use by year, sourced from the 
annual DANMAP reports. According to the table, swine production has continually increased, 
with antibiotic levels eventually levelling off in 2009 before sharply falling. Even after Levy’s 
discoveries, production continues to expand. With improved production methods and less 
disease, the livestock industry in Denmark profited from the ban on non-therapeutic antibiotic 
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use (Levy; Rogers). Viewing Denmark as a case study, through multidisciplinary action 
involving health researchers, government legislators, farmers, and veterinarians, progress 
mutually beneficial to human and animal health and economic interests is within reach. 
Danish Swine Production and Antibiotics Sold 1990-2016 
Year Production (millions) Antibiotics Used (million kg) 
1990 16.425 -- 
1992 18.442 -- 
1994 20.651 -- 
1996 20.424 -- 
1998 22.738 -- 
2000 22.414 -- 
2001 23.199 69,418 
2002 24.203 72,833 
2003 24.434 80,948 
2004 25.141 92, 690 
2005 25.758 92,532 
2006 25.763 91,405 
2007 26.311 97,751 
2008 27.078 97,013 
2009 27.603 103,697 
2010 28.505 100,527 
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2011 29.399 81,443 
2012 29.047 85,870 
2013 28.996 90,606 
2014 29.926 86,020 
2015 30.874 81,499 
2016 31.660 78,150 
 
Source: Danish Integrated Antimicrobial Resistance Monitoring and Research Programme, DANMAP. 2001-2016. 
Denmark’s multi-dimensional plan of action includes strict mandatory components, 
which contrasts with the voluntary nature of FDA GFI #213. For example, the table above 
indicates a rise in antibiotic use on Danish swine operations from the early 2000s through 2009. 
The production is listed in the millions of heads, while the total antibiotics used is a sum of 
antibiotics used at each denoted age. Though the antibiotics were used for therapeutic purposes, 
this unrelenting rise was worrying. Legislators enacted the Yellow Card Initiative using the 
detailed data VetStat and DANMAP collected. This regulation set concrete limits of antibiotics 
for swine producers, which veterinarian authorities enforced with compulsory antibiotic 
reductions and fines (“DANMAP 2016”). Enforcement was possible because of the Danish 
Central Husbandry Register (CHR), which assigns each farm a number, and collects business 
and geographic data such as ownership, farm size, livestock type and number (“DANMAP 
2016”).  
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What the United States can learn from Denmark 
 American legislators, public health officials, and members of the agricultural industry can 
modify the strategies that Danish legislators and researchers employed to improve the antibiotic 
resistance outlook. First of all, comprehensive, detailed, and accurate surveillance of agricultural 
antibiotic use is crucial. The FDA does not have the surveillance capabilities necessary to impose 
parameters of antibiotic use because of the OTC status of many antimicrobials, along with a 
dearth of geographically targeted pharmaceutical records due to legal protections for industry. 
This is evident in the multiple gaps and loopholes within FDA GFI #213. An exemplary system 
to emulate would be VetStat in Denmark, which collects data daily from pharmacies in order to 
accurately track antibiotic use in food-producing animals (“DANMAP 2016”). The Expert 
Commission on Addressing the Contribution of Livestock to the Antibiotic Resistance Crisis 
recommended that the CDC, FDA, and USDA, “should publish a joint, integrated report that 
summarizes the following: antibiotic resistance data, antibiotic sales, antibiotic use data, and 
livestock production statistics” in order to modernize and streamline the scattered antibiotic 
resistance surveillance programs (Expert Commission). Knowing where, how, why, and what 
drugs are dispensed to food producing animals is essential in providing a strong scientific basis 
to not only target overuse, but to create a convincing report to impress upon government 
legislators the urgency of addressing this public health crisis.  
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Data Summary 
Before continuing to the final conclusions of this study, it is necessary to briefly 
summarize the main evidence and findings explained in-depth above. For decades, the 
agricultural industry has been using antibiotics for two main reasons: disease treatment and 
production purposes. Today, in the United States, 70% of all antibiotics used are for food-
producing animals (Boris). That equates to nearly 28 million pounds of antibiotics annually 
(Boris). Because of the close-quarters animals are subject to on factory farms, disease spreads 
quickly. To combat this, low doses of antibiotics are provided through feed or water to prevent 
disease. This results in meat and food products contaminated with the same low doses of 
antibiotics, exposing human consumers (Boris). According to the CDC, one in five cases of 
resistant infections is the result food-borne pathogens like E. coli, and clearly cites the 
connection between agricultural antibiotic use and antibiotic resistance in humans. Sub-
therapeutic doses in animal feed or water are used for production purposes of preventing disease 
and encouraging faster weight gain. The FDA, however, does not consider disease prevention as 
a production purpose, unlike countries in the European Union. The FDA seems to be caught in 
the middle, attempting to serve both public health and industry interests.  
In 2013, the FDA unveiled GFI #213. The voluntary regulation’s purpose was to decrease 
agricultural antibiotic use by relabeling medically important drugs from OTC to VFD or 
prescription only. However, there are significant weaknesses in the policy. First off, it is not 
legally binding, and operates only as a suggestion to pharmaceutical companies. These 
companies also disagree with the FDA over which drugs are considered medically important. 
Also, even though antibiotics now cannot be used for production purposes, the FDA considers 
sub-therapeutic dosages for disease prevention a therapeutic use. Veterinarian oversight is also 
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subjective when prescribing antibiotics. Finally, though there is a timeline for voluntarily 
adopting these measures. There is not a current plan in place for failures.  
The FDA annual reports detailing antibiotic distribution highlight the current inefficacy 
of GFI #213. From 2009 through 2016, total antibiotic sales actually rose by 11%. Furthermore, 
even though GFI #213 specifically targeted reducing OTC consumption, as of 2016, 96% of all 
antimicrobials distributed were still categorized as OTC dispensing status. This marks only a 2% 
drop since 2013. The data itself is subject to questioning, due to the fact that drugs with 
production uses and therapeutic uses are grouped together, making it difficult to determine if 
there has been any decline in specific dispensing reasons. This is due to the preservation of 
business confidentiality, and demonstrates industry bias by the FDA. 
Conversely, Denmark has a robust and proactive surveillance and policy system in place 
that has proved successful in eliminating non-therapeutic antibiotic use in agriculture, while 
decreasing the amounts of medically-important drugs overall. According to Hammerum et al, 
“Denmark was the first country to establish a systematic and continuous monitoring program of 
antimicrobial drug consumption and antimicrobial agent resistance in animals, food, and 
humans” (Hammerum et al). This comprehensive surveillance system is known as the Danish 
Integrated Antimicrobial Resistance Monitoring and Research Program (DANMAP), and 
continues to collect vital data used in epidemiological and public health research today through 
the Danish Central Husbandry Register (CHR). The CHR assigns each farm a number, and 
collects business and geographic data such as ownership, farm size, livestock type and number 
(“DANMAP 2016”). The FDA does not have the surveillance capabilities necessary to impose 
parameters of antibiotic use. Denmark’s complex plan of action includes strict mandatory 
components, which contrasts with the voluntary nature of FDA GFI #213. This holistic approach 
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reduced antibiotic overuse by addressing industry pressures, for example, the Danish government 
enacted regulations restricting profits that veterinarians could receive from drug sales. 
Throughout the late 1990s, Denmark continued to monitor environmental antibiotic resistance 
and by 1999, eradicated all non-therapeutic antibiotic use in swine operations, which led to an 
increase of production from 18.4 million weaning pigs in 1992 to 27.1 million in 2008 (Levy).  
The FDA foremost needs comprehensive, detailed, and accurate surveillance of 
agricultural antibiotic use, such as VetStat in Denmark, which collects data daily from 
pharmacies in order to accurately track antibiotic use in food-producing animals (“DANMAP 
2016”). Knowing where, how, why, and what drugs are dispensed to food producing animals is 
essential in providing a strong scientific basis to target overuse and provide accurate data on 
which to base reduction policy efforts. 
Further Conclusions  
While voluntary change to how antibiotics are labelled and disseminated aids in 
surveillance, this only remedies the symptoms. The causes that drive the need for continued 
antibiotic use are the farm conditions and the economic push for low price and high quantity. By 
the end of 2018, the FDA will release the 2017 annual report, which marks the official end of the 
three-year voluntary adoption period. Perhaps the data will indicate a continuation of the 2015-
2016 decrease in overall consumption, but will this be enough? Pharmaceuticals and industry 
will no doubt continue to resist regulation in court, proverbially tying the FDA’s hands. 
However, this delay could lead to a multi-drug resistant disease outbreak among humans. 
Unfortunately, it seems likely a disease emergence would be the double-edged sword necessary 
to targeting agricultural antibiotic abuse. There would finally be an undisputable direct link 
between animal resistance and subsequent human infection in the United States. Regardless of 
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what the future may bring, the time to act is now. First, the U.S. needs to emulate and create an 
adaptation of Denmark’s multi-disciplinary approach to reducing non-therapeutic antibiotic use, 
and identifying current challenges. This includes detailed antibiotic use surveillance in humans 
and animals, and adopting strong enforcement policies, such as taxing antimicrobials used in 
agriculture, and providing subsidies for antibiotic alternatives (“Review”). Reacting in a 
meaningful way to continue to monitor and improve the AMR outlook for both humans and 
animals is absolutely vital. Antibiotic resistance is fundamentally a global health threat due to the 
ever-increasing interconnectedness of the world today. People, animals, and products are 
constantly crossing borders, bringing pathogens along with them. With growing amounts of 
resistance and limited options of treatment, slowing down the proliferation of antibiotic resistant 
pathogens is crucial to human, animal, and environmental health.  
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Notes on Methodology Reasoning and Research Technique Discussion 
This study emphasized a multi-disciplinary methodology in order to underscore the facets 
involved in public health policy creation. The final structure of the paper reflects the main 
purpose—to highlight domestic policy strengths and weaknesses, and to improve proactive 
policy formation by adopting successful tactics used globally. FDA GFI #213, as a harbinger of 
FDA efforts to finally curb antibiotic overuse, acts as a case study. According to FDA GFI #213, 
FDA GFI #209 and VFD are to be used in conjunction with FDA GFI #213 as part of a joint plan 
to reduce and control medically important antibiotic use in livestock. Thus, FDA GFI #209 and 
the Veterinary Feed Directive (VFD) were used to determine similarities in structure as well as 
to demonstrate continuity among FDA regulation efforts. Additionally, this study identified 
select motivations of pharmaceutical corporations, agricultural associations, veterinary institutes, 
and public health organizations invested in the issue of agricultural antibiotic use that may have 
influenced the composition of FDA GFI #213. To ascertain these influences within FDA GFI 
#213’s composition, this study reviewed documents from the CDC and WHO (mission 
statements and releases) that declare an aggressive stance and public health action plan for 
antibiotic resistance. Ultimately, this will help to provide further insight to the motivations and 
audience (both explicit and implicit) of FDA GFI #213, to gain a more accurate picture of the 
goals of the regulatory document and whether it acts in the best interest of public health.  
Determining the effectiveness of voluntary regulations that FDA GFI #213 set forth had 
two parts—first, this study examined the benefits of voluntary regulation in general from a legal 
standpoint, then focused on the structure and capability of FDA GFI #213. To establish the 
strengths of voluntary regulation, the FDA’s statements and studies justifying the FDA GFI #213 
were examined, as well as a review of peer-reviewed journal articles about the health and 
Drake 38 
 
economic implications of FDA voluntary regulations. These journal articles provided additional 
perspectives on FDA regulatory techniques and the health consequences in regards to antibiotic 
resistance. A balanced view is necessary to discover relevant subtext within the issue and 
evidence that may need further research. 
To research whether FDA GFI #213 led to a significant decrease in agricultural antibiotic 
use, this study examined antibiotic sales and usage amounts from the years of 2009 to 2016. The 
FDA’s annual “Summary Report On Antimicrobials Sold or Distributed for Use in Food-
Producing Animals” provided numerical data. This document listed the drug classifications, 
route of administration, dispensing status, estimates of drug use itemized by species, and 
provides multi-year trends on agricultural antibiotic use. By comparing antibiotic use with a 
timeline of before and after the release FDA GFI #213, this study reliably concluded the 
inefficacy of current FDA voluntary regulations.  
Finally, this study compared domestic FDA regulation status with the widely successful 
policy strategies in Denmark. Differences in policy enforcement, data collection and sourcing, 
along with comprehensive surveillance techniques provided and integrated approach not only in 
comparing the United States with Denmark, but in piecing together a more cohesive and 
aggressive policy arrangement. In summation, this study concluded the FDA’s Guidance for 
Industry #213 exemplifies how voluntary regulations do not have the ability to decrease 
antibiotic use in livestock, thus proving ineffective in combating the proliferation of antibiotic 
resistance. The balance between economic and public health concerns present in the structure of 
FDA GFI #213 influence the medical consequences of antibiotic resistance exposure for global 
human health. While FDA GFI #213 is foremost an agricultural policy issue, agricultural 
antibiotic contamination in the environment and subsequent antibiotic resistant infections are a 
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threat to human health. This methodology is only one of many different approaches to evaluating 
policy efforts, each just as important when investigating such a vast yet vital crisis. 
However, there are contingencies to account for in this methodology. In recent years, the 
FDA has improved surveillance techniques of antibiotic resistance such as the National 
Antimicrobial Resistance Monitoring System (NARMS), as well as documentation of antibiotic 
use in agriculture, such as the USDA’s National Animal Health Monitoring System (NAHMS). 
Perhaps this improvement in accuracy accounts for an apparent rise in antibiotic use. These 
methods of surveillance have notable limitations regarding data reporting in order to protect 
confidential business information. In recognition of this, the thesis noted both antibiotic 
resistance monitoring systems and their weaknesses. There may be other factors that contribute 
to an increase in agricultural antibiotic use, such as USDA regulations regarding livestock 
operation conditions and other environmental factors. In addition, the comparison of Danish 
policies is not meant to act as a default example of success, owing to the fact that the Danish 
legislative process, confidentiality rights, and agricultural industry operates under different 
structures. These points were taken into consideration while conducting research and forming 
conclusions. 
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Keywords 
For the sake of clarity and consistency in analyzing policy, significant technical terms 
central to FDA GFI #213 must be defined. The wording of the document contains essential terms 
with specific FDA definitions vital to understanding the purpose and regulatory meaning given 
to suggestions listed for drug sponsors. Without a shared understanding of the official FDA 
meaning of terms like judicious use of antibiotics, antibiotics important to human health, and 
non-therapeutic use, there could be conflicts regarding the goals and methods of FDA GFI #213, 
as different groups (such as CDC or National Pork Producers) may give different meaning to 
those terms. This will be reflected in the study of the language used within FDA GFI #213, 
relating to enforcement issues and economic preference. Thus, for uniformity, this study uses 
definitions provided by the FDA. Antibiotic resistance: a subsection within antimicrobial 
resistance, defined as when bacteria become immune to a drug after exposure. 
Central Husbandry Register (CHR): This is a register of all Danish farms defined as geographical 
sites housing production animals. It contains information concerning ownership, farm size, 
animal species, age groups, number of animals and production type. Each farm has a unique farm 
identity number (CHR-number). 
Concentrated Animal Feeding Operation (CAFO): a large animal feeding operation where a large 
population of animals are raised within a small land area. Population size varies by species and 
can be found at: 
https://www.nrcs.usda.gov/wps/portal/nrcs/main/national/plantsanimals/livestock/afo/ 
Document/Regulation: refers to interchangeable names referring to GFI #213, may also include 
“regulatory document.” 
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Food-producing animals: includes any animal either directly consumed or whose bi-products are 
consumed.  
Judicious use: The use of medically important antimicrobial drugs in food-producing animals 
“should be limited to those uses that are considered necessary for assuring animal health,” and 
“should be limited to those uses that include veterinary oversight or consultation.” 
Medically important antibiotics: directly cites the full list of drugs found in FDA GFI #209 
Appendix A that are vital in treating human disease. This list is not static and is subject to change 
with the introduction of new drugs and current disease outbreaks. 
National Animal Health Monitoring System (NAHMS): USDA surveillance program that 
monitors the health and health management of domestic livestock populations 
Non-therapeutic antibiotic use: is interchangeable with the FDA term “production purposes,” 
which refers to, “the use of antibiotics with the intent of enhancing growth or improving feed 
efficiency.”  
  
Drake 42 
 
Works Cited 
Boris, Lynn M. "The food-borne ultimatum: proposing federal legislation to create humane 
 living conditions for animals raised for food in order to improve human health." Journal 
 of Law and Health, Summer 2011, p. 285+. 
Centers for Disease Control and Prevention. “Antibiotic / Antimicrobial Resistance.” Centers for 
 Disease Control and Prevention, 18 Aug. 2017, www.cdc.gov/drugresistance/index.html. 
Collignon, Peter, and Voss, Andreas. “China, What Antibiotics and What Volumes Are Used in 
 Food Production Animals?” Antimicrobial Resistance and Infection Control, vol. 4, no. 1, 
 2015, pp. Antimicrobial Resistance and Infection Control, April 23, 2015, Vol.4(1). 
Davis, Rutkow, Meghan, Lainie. “Regulatory Strategies to Combat Antimicrobial Resistance of 
 Animal Origin: Recommendations for a Science-Based U.S. Approach.” Tulane 
 Environmental Law Journal., vol. 25, no. 2, 2012, pp. 327–388. 
Eskridge, Nacy. “Feed Additive Controversy: Congress Stops FDA from Restricting Use of 
 Antibiotics.” BioScience., vol. 28, no. 9, 2012, pp. 557–559. 
Expert Commission on Addressing the Contribution of Livestock to the Antibiotic Resistance 
 Crisis. “Combatting Antibiotic Resistance: A Policy Roadmap to Reduce Use of 
 Medically Important Antibiotics in Livestock.” 2017, https://tinyurl.com/y9xhmr6z. 
Hammerum, Anette M., et al. “Danish Integrated Antimicrobial Resistance Monitoring and 
 Research Program. (PERSPECTIVE) (Clinical Report).” Emerging Infectious Diseases, 
 vol. 13, no. 11, 2007, pp. 1632–9. 
Hao, Haihong et al. “Benefits and Risks of Antimicrobial Use in Food-Producing Animals.” 
 Frontiers in Microbiology 5 (2014): 288. PMC. 17 Oct. 2017. 
Drake 43 
 
Heinzerling, Lisa. “The FDA's Continuing Incapacity on Livestock Antibiotics.” Stanford 
 Environmental Law Journal, vol. 33, 2014, pp. 325–457. 
Infectious Diseases Society of America. “Combating Antimicrobial Resistance: Policy 
 Recommendations to Save Lives.” Clinical Infectious Diseases., vol. 52, no. 5, 2011, pp. 
 S397–S428. 
Khachatourians, George G. "Agricultural use of antibiotics and the evolution and transfer of 
 antibiotic-resistant bacteria." Canadian Medical Association Journal, vol. 159, no. 9, 
 1998, pp. 1129-1136.  
Landers, Timothy F. et al. “A Review of Antibiotic Use in Food Animals: Perspective, Policy, 
 and Potential.” Public Health Reports, vol. 127, no. 1, 2012, pp. 4–22. 
Laxminarayan, Ramanan, et al. The Economic Costs of Withdrawing Anti-Microbial Use in the 
 Livestock Sector. Paris, Organisation for Economic Cooperation and Development 
 (OECD), 2015. 
Levy, Sharon. “Reduced Antibiotic Use in Livestock: How Denmark Tackled Resistance.” 
 Environmental Health Perspectives, vol. 122, no. 6, 2014, pp. A160–5. 
Maron, Dina Fine, et al. “Restrictions on Antimicrobial Use in Food Animal Production: An 
 International Regulatory and Economic Survey.” Globalization and Health, vol. 9, 2013, 
 p. 48+. 
Marshall, Bonnie M., and Stuart B. Levy. “Food Animals and Antimicrobials: Impacts on 
 Human Health.” Clinical Microbiology Reviews 24.4 (2011): 718–733. PMC. Web. 8 
 Apr. 2018. 
Drake 44 
 
National Agricultural Statistics Service (NASS), Agricultural Statistics Board, U.S. Department 
 of Agriculture. “Quarterly Hogs and Pigs.” 27 March, 2009, 
 https://tinyurl.com/y9opcuvk.  
National Agricultural Statistics Service (NASS), Agricultural Statistics Board, U.S. Department 
 of Agriculture. “Quarterly Hogs and Pigs.” 26 March, 2010, 
 https://tinyurl.com/yb2nxz7q.  
National Agricultural Statistics Service (NASS), Agricultural Statistics Board, U.S. Department 
 of Agriculture. “Quarterly Hogs and Pigs.” 25 March, 2011, 
 https://tinyurl.com/yd2eqqy5.  
National Agricultural Statistics Service (NASS), Agricultural Statistics Board, U.S. Department 
 of Agriculture. “Quarterly Hogs and Pigs.” 30 March, 2012, 
 https://tinyurl.com/y7zbsuz7.  
National Agricultural Statistics Service (NASS), Agricultural Statistics Board, U.S. Department 
 of Agriculture. “Quarterly Hogs and Pigs.” 28 March, 2013, 
 https://tinyurl.com/yclhuafe.  
National Agricultural Statistics Service (NASS), Agricultural Statistics Board, U.S. Department 
 of Agriculture. “Quarterly Hogs and Pigs.” 28 March, 2014, 
 https://tinyurl.com/y7rrap5z.  
National Agricultural Statistics Service (NASS), Agricultural Statistics Board, U.S. Department 
 of Agriculture. “Quarterly Hogs and Pigs.” 27 March, 2015, 
 https://tinyurl.com/yb7d2m8o.  
Drake 45 
 
National Agricultural Statistics Service (NASS), Agricultural Statistics Board, U.S. Department 
 of Agriculture. “Quarterly Hogs and Pigs.” 25 March, 2016, 
 https://tinyurl.com/y7ma6yva.  
Neff, Roni, et al. “A Food Systems Approach to Healthy Food and Agriculture Policy.” Health 
 Affairs, vol. 34, no. 11, 2015, pp. 1908–1A. 
Orrico, Lauren. “Squashing the Superbugs: A Proposed Multifaceted Approach to Combating 
 Antibiotic-Resistant Bacteria.” Journal of Law and Health., vol. 27, no. 2, 2014, pp. 259–
 292. 
Podolsky, Scott H. The Antibiotic Era Reform, Resistance, and the Pursuit of a Rational 
 Therapeutics. Baltimore, Johns Hopkins University Press, 2014. 
Review on Antimicrobial Resistance. “Antimicrobials in Agriculture and the Environment: 
 Reducing Unnecessary Use and Waste.” December 2015, http://tinyurl.com/l82nvmk. 
Rogers, Laura. “Avoiding Antibiotic Resistance: Denmark’s Ban on Growth Promoting 
 Antibiotics in Food Animals.” The PEW Charitable Trusts: The Pew Campaign on 
 Human Health and Industrial Farming. https://tinyurl.com/yb3axuan. 
Rosso Grossman, Margaret. “USA: Recent FDA Regulatory Measures.” European Food and  
 Feed Law Review., vol. 9, no. 1, 2014, pp. 60–62. 
Schmidt, Charles W. “Antibiotic Resistance in Livestock: More at Stake than Steak. 
 (Focus).” Environmental Health Perspectives, vol. 110, no. 7, 2002, pp. A396–A402. 
Smith, Tara C., and Joseph Heitman. “Livestock-Associated Staphylococcus Aureus: The United 
 States Experience.” Vol. 11, no. 2, 2015, p. e1004564. 
Drake 46 
 
Statens Serum Institut, Danish Veterinary and Food Administration, Danish Medicines Agency, 
 Danish Veterinary Institute. “DANMAP 2001.” DANMAP. July 2002, 
 https://tinyurl.com/yb5qt4by. 
Statens Serum Institut, Danish Veterinary and Food Administration, Danish Medicines Agency, 
 Danish Veterinary Institute. “DANMAP 2002.” DANMAP. July 2003, 
 https://tinyurl.com/ybxhnyy2. 
Statens Serum Institut, Danish Veterinary and Food Administration, Danish Medicines Agency, 
 Danish Institute for Food and Veterinary Research. “DANMAP 2003.” DANMAP. July 
 2004, https://tinyurl.com/y72jv48g. 
Statens Serum Institut, Danish Veterinary and Food Administration, Danish Medicines Agency, 
 Danish Institute for Food and Veterinary Research. “DANMAP 2004.” DANMAP. July 
 2005, https://tinyurl.com/y8l2xqo6. 
Statens Serum Institut, Danish Veterinary and Food Administration, Danish Medicines Agency, 
 Danish Institute for Food and Veterinary Research. “DANMAP 2005.” DANMAP. July 
 2006, https://tinyurl.com/y7baokjs. 
Statens Serum Institut, Danish Veterinary and Food Administration, Danish Medicines Agency, 
 National Veterinary Institute, National Food Institute. “DANMAP 2006.” DANMAP. 
 September 2007, https://tinyurl.com/yc5dco4h. 
Statens Serum Institut, Danish Veterinary and Food Administration, Danish Medicines Agency, 
 National Veterinary Institute, National Food Institute. “DANMAP 2007.”  DANMAP. 
 September 2008, https://tinyurl.com/y9mm5g85. 
Drake 47 
 
Statens Serum Institut, Danish Veterinary and Food Administration, Danish Medicines Agency, 
 National Veterinary Institute, National Food Institute. “DANMAP 2008.”  DANMAP. 
 September 2009, https://tinyurl.com/y8ey4k62. 
Statens Serum Institut, National Veterinary Institute, National Food Institute, Danish Veterinary 
 and Food Administration, Danish Medicines Agency. “DANMAP 2009.” DANMAP. 
 September 2010, https://tinyurl.com/y8qcoooy. 
Statens Serum Institut, National Veterinary Institute, National Food Institute. “DANMAP 2010.” 
 DANMAP. August 2011, https://tinyurl.com/y89d3ynu. 
Statens Serum Institut, National Veterinary Institute, National Food Institute. “DANMAP 2011.” 
 DANMAP. September 2012, https://tinyurl.com/ybxertdp. 
Statens Serum Institut, National Veterinary Institute, National Food Institute. “DANMAP 2012.” 
 DANMAP. September 2013, https://tinyurl.com/yb82d2mt. 
Statens Serum Institut, National Veterinary Institute, National Food Institute. “DANMAP 2013.” 
 DANMAP. September 2014, https://tinyurl.com/y6vgbkap. 
Statens Serum Institut, National Veterinary Institute, National Food Institute. “DANMAP 2014.” 
 DANMAP. September 2015, https://tinyurl.com/yb8abmk5. 
Statens Serum Institut, National Veterinary Institute, National Food Institute. “DANMAP 2015.” 
 DANMAP. November 2016, https://tinyurl.com/y7tlumwm. 
Statens Serum Institut, National Veterinary Institute, National Food Institute. “DANMAP 2016.” 
 DANMAP. October 2017, https://tinyurl.com/yakpbgdo. 
United States, Department of Health and Human Services, Food and Drug Administration, 
 Center for Veterinary Medicine. “2012 Summary Report On Antimicrobials Sold or 
Drake 48 
 
 Distributed for Use in Food-Producing Animals.” September 2013, 
 https://tinyurl.com/ybr8y2hd. 
United States, Department of Health and Human Services, Food and Drug Administration, 
 Center for Veterinary Medicine. “2014 Summary Report On Antimicrobials Sold or 
 Distributed for Use in Food-Producing Animals.” December 2015, 
 https://tinyurl.com/ycdgrua3.  
United States, Department of Health and Human Services, Food and Drug Administration, 
 Center for Veterinary Medicine. “2015 Summary Report On Antimicrobials Sold or 
 Distributed for Use in Food-Producing Animals.” December 2016, 
 https://tinyurl.com/ycjnoz96. 
United States, Department of Health and Human Services, Food and Drug Administration, 
 Center for Veterinary Medicine. “2016 Summary Report On Antimicrobials Sold or 
 Distributed for Use in Food-Producing Animals.” December 2017, 
 https://tinyurl.com/yathvvp8. 
United States, Department of Health and Human Services, Food and Drug Administration, 
 Center for Veterinary Medicine. “Guidance for Industry #209.” April 2012, 
 https://tinyurl.com/y8zeuv64. 
United States, Department of Health and Human Services, Food and Drug Administration, 
 Center for Veterinary Medicine. “Guidance for Industry #213.” December 2013,  
 https://tinyurl.com/ybkn2uk5. 
Van den Bogaard, A. E., et al. “The Effect of Banning Avoparcin on VRE Carriage in The 
 Netherlands.” Journal of Antimicrobial Chemotherapy, vol. 46, no. 1, 2000, pp. 146–148. 
Drake 49 
 
Ying, Guang-Guo, et al. “China Must Reduce Its Antibiotic Use.” Environmental Science & 
 Technology, vol. 51, no. 3, 2017, pp. 1072–1073. 
 
